Older H1 Antihistamines Repurposed for MCAS
US Availability and Clinical Context
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Overview
Several older medications with histamine H1–blocking activity have been used off-label to manage mast cell activation syndrome (MCAS). These include ketotifen, cyproheptadine, hydroxyzine, diphenhydramine, chlorpheniramine, clemastine, and the tricyclic antidepressant doxepin. This review also includes rupatadine — a second-generation H1 antihistamine with PAF-antagonist activity — because restricting the discussion to first-generation agents alone would be unnecessarily narrow.
All are available in the United States — some over the counter, some by prescription, and two (oral ketotifen and rupatadine) through compounding pharmacies or importation.
The key pharmacologic distinction is between drugs that primarily block the effects of released histamine and drugs that bring additional actions to the table — serotonin antagonism (cyproheptadine), mast-cell stabilization (ketotifen), or combined H1/H2 blockade from a non-antihistamine drug class (doxepin).
Their use in MCAS is supported largely by expert consensus, clinical experience, and evidence extrapolated from mastocytosis and other related mast-cell disorders — not by robust MCAS-specific randomized controlled trials. Dosing is intentionally omitted from this article because it must be individualized for each client.
Medication Profiles
Ketotifen, oral
Zaditen (brand not marketed in the US — compounded oral formulations)
Original role: Older H1 antihistamine with mast-cell–stabilizing properties
Why it is used in MCAS: Combines histamine blockade with mast-cell–stabilizing activity. Considered when second-generation H1 blockers alone are insufficient. The stabilizing component sets it apart from conventional antihistamines.
US availability: Oral ketotifen is not commercially available in the US and must be obtained through a compounding pharmacy. OTC ketotifen eye drops (Zaditor, Alaway) are NOT a substitute for oral therapy.
Important limitations: Sedation can be dose-limiting. Evidence includes small studies in mastocytosis rather than large MCAS-specific trials.
Cyproheptadine
Periactin (generic widely available)
Original role: First-generation H1 antihistamine with serotonin-antagonist and anticholinergic activity
Why it is used in MCAS: The AAAAI MCAS work-group report specifically describes its use for diarrhea and nausea in MCAS, leveraging its antiserotonin properties for GI-predominant symptoms.
US availability: Available by prescription in the US as generic tablets and oral syrup. No compounding required.
Important limitations: Sedation, appetite stimulation, weight gain, and anticholinergic effects. Inclusion in expert guidance does not establish efficacy in controlled MCAS trials.
Doxepin
Sinequan, Silenor (generic available)
Original role: Tricyclic antidepressant with potent H1- and H2-blocking activity
Why it is used in MCAS: The clearest example of cross-category repurposing — an antidepressant used for its antihistamine properties. Discussed in the AAAAI report for potential CNS-predominant MCAS symptoms.
US availability: Available by prescription in the US as generic capsules and oral solution. Low-dose Silenor is FDA-approved for insomnia. Higher antihistamine doses are prescribed off-label.
Important limitations: Not a selective H1 blocker. Sedation, anticholinergic effects, cardiac conduction concerns, and possible cognitive impairment. Requires careful dose titration.
Hydroxyzine
Atarax, Vistaril (generic widely available)
Original role: Sedating first-generation H1 antihistamine and anxiolytic
Why it is used in MCAS: Used to control itching, urticaria, and other histamine-mediated symptoms. Some comparative evidence exists in mastocytosis. Anxiolytic properties may benefit clients with anxiety-predominant presentations.
US availability: Available by prescription in the US as generic tablets (hydroxyzine HCl) and capsules (hydroxyzine pamoate). No compounding required.
Important limitations: Sedation limits daytime use. Comparative evidence derives partly from mastocytosis rather than consensus-defined MCAS. Second-generation agents are generally preferred for maintenance.
Diphenhydramine
Benadryl (OTC, generic widely available)
Original role: Sedating first-generation H1 antihistamine
Why it is used in MCAS: Used for acute symptomatic histamine blockade. Often part of anaphylaxis adjunctive protocols (after epinephrine). Not ideal for daily maintenance.
US availability: Available OTC in the US in multiple formulations (tablets, capsules, liquid). No prescription or compounding required.
Important limitations: Sedation, anticholinergic burden, and cognitive effects make it a poor choice for routine maintenance. Does NOT replace epinephrine for anaphylaxis.
Chlorpheniramine
Chlor-Trimeton (OTC, generic widely available)
Original role: First-generation H1 antihistamine
Why it is used in MCAS: Listed among symptomatic treatment options for mast-cell disease. Blocks histamine effects at H1 receptors.
US availability: Available OTC in the US as tablets and syrup. No prescription or compounding required.
Important limitations: Primarily symptom-blocking — should not be described as a mast-cell stabilizer. Sedation and anticholinergic effects. Newer agents generally preferred.
Clemastine
Tavist (OTC, generic available)
Original role: First-generation H1 antihistamine
Why it is used in MCAS: Another older antihistamine listed for mast-cell disease symptom management.
US availability: Available OTC in the US as tablets. No prescription or compounding required.
Important limitations: First-generation adverse-effect profile (sedation, dry mouth) generally makes newer agents preferable for ongoing treatment.
Rupatadine: A Second-Generation Antihistamine Repurposed for Mast-Cell Disorders
Rupatadine is not a first-generation antihistamine, but restricting this review to first-generation agents would be unnecessarily narrow. It belongs here because the broader question is about established medications repurposed for MCAS — and rupatadine fits that definition.
Rupatadine, oral
Rupafin, Pafinur (not FDA-approved in the US — compounded or imported)
Drug class: Second-generation H1 antihistamine with platelet-activating factor (PAF) antagonist activity
Why it is used in mast-cell disorders: Combines H1 blockade with PAF antagonism. Unlike most agents on this list — which are supported only by mechanistic reasoning or clinical experience — rupatadine has a small randomized, placebo-controlled trial demonstrating improved symptoms and quality of life in adults with mastocytosis.
US availability: Rupatadine is not FDA-approved in the United States. It is approved in Europe and other markets. US clinicians who want to use it must obtain it through a compounding pharmacy or patient importation pathways.
Important limitations: Evidence specifically establishing efficacy in consensus-defined MCAS remains limited. The key trial was conducted in mastocytosis, not idiopathic MCAS, and used placebo — not another antihistamine — as the comparator. GI symptoms did not significantly improve in that trial. Whether the PAF-antagonist component contributes additional benefit beyond H1 blockade remains unproven.
Key clinical study:
Siebenhaar F, et al. "Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial." Allergy. 2013;68(7):949–952. DOI: 10.1111/all.12159.
This trial supports symptomatic benefit in mastocytosis. It does not establish efficacy across all MCAS subtypes, prove superiority to other H1 antihistamines, or determine whether PAF antagonism contributed additional benefit beyond H1 blockade.
Which Drugs Are Genuinely "Repurposed"?
Doxepin is the clearest example of repurposing across therapeutic categories — an antidepressant deployed for its potent antihistamine activity.
Cyproheptadine represents an older antihistamine whose additional serotonin antagonism provides a specific rationale for GI-predominant MCAS symptoms like diarrhea and nausea.
Ketotifen occupies its own niche because it combines H1 blockade with mast-cell–stabilizing properties — a mechanistic difference from simple histamine blockade.
Rupatadine stands apart as a second-generation agent, but its dual H1/PAF antagonism and the existence of a randomized trial in mastocytosis earn it a place in this discussion. It is the only drug on this list with a placebo-controlled crossover trial specifically in mast-cell disease.
By comparison, using hydroxyzine, diphenhydramine, chlorpheniramine, or clemastine for histamine-mediated MCAS symptoms is better described as extending their established antihistamine use to a related disorder — not discovering a new mechanism or demonstrating a new disease-specific treatment.
What the Evidence Supports — and Does Not Support
The literature supports these medications as symptom-directed options, but several distinctions matter for honest clinical communication:
●Blocking histamine is not the same as stopping mast-cell activation. Ordinary H1 antihistamines reduce histamine-mediated effects downstream — they should not all be labeled mast-cell stabilizers.
●Mastocytosis evidence does not automatically apply to MCAS. These conditions share mediator-related symptoms but differ diagnostically. Treatment findings from one cannot be assumed to transfer completely to the other.
●Expert recommendations are not randomized-trial proof. The AAAAI report notes that antihistamine recommendations for mast-cell activation disorders rely on expert opinion. More recent reviews emphasize the need for controlled treatment trials.
●Older does not mean more effective. Current approaches generally favor second-generation H1 antihistamines (fexofenadine, cetirizine, loratadine) for maintenance because of their more favorable adverse-effect profiles. Older agents play selected roles when symptoms remain inadequately controlled or when their additional pharmacology is specifically useful.
Key Scholarly References
1. Weiler CR, et al. "AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management." Journal of Allergy and Clinical Immunology. 2019;144:883–896. DOI: 10.1016/j.jaci.2019.08.023.
The most directly relevant source for the MCAS-specific discussion of cyproheptadine and doxepin.
2. Theoharides TC, Tsilioni I, Ren H. "Recent advances in our understanding of mast cell activation — or should it be mast cell mediator disorders?" Expert Review of Clinical Immunology. 2019;15(6):639–656. DOI: 10.1080/1744666X.2019.1596800.
Useful for comparing the pharmacologic roles of conventional antihistamines, cyproheptadine, doxepin, ketotifen, and rupatadine.
3. Siebenhaar F, et al. "Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial." Allergy. 2013;68(7):949–952. DOI: 10.1111/all.12159.
The key clinical trial supporting rupatadine in mast-cell disease — 30 adults with mastocytosis in a crossover design.
4. "Mast cell activation syndrome: Current understanding and research needs." 2024.
Provides context for the limitations of existing treatment evidence and the need for prospective, placebo-controlled studies.
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon. Founder of the LDN Support Group.
Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com
